Review



ccl21 recombinant protein  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    R&D Systems ccl21 recombinant protein
    Ccl21 Recombinant Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 18 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ccl21 recombinant protein/product/R&D Systems
    Average 93 stars, based on 18 article reviews
    ccl21 recombinant protein - by Bioz Stars, 2026-03
    93/100 stars

    Images



    Similar Products

    94
    Innovative Research Inc recombinant murine plasmin
    A soluble proteoform of CCL21 (CCL21-ΔC) with chemotactic activity is present in murine skin and increased in CHS-inflamed skin. (A) Representative western blot of CCL21 performed on steady-state (CTR) and CHS-inflamed (CHS) murine ear skin protein extracts. <t>Recombinant</t> CCL21 was loaded as a CTR. (B) Western blot analysis of recombinant human full-length CCL21 and CCL21-ΔC protein. One out of two experiments is shown. (C) Quantification of the full-length CCL21 (gray) and CCL21-ΔC (white) relative band percentages. Pooled data from n = 4 independent biological replicates. (D) ELISA-based quantification of total CCL21 in tissue protein extracts, performed with antibody clone AF457, which detects full-length CCL21 and CCL21-ΔC. Pooled data from n = 5 mice/condition. Statistics: unpaired Student’s t test. (E–J) Skin elution assay and analyses were performed on the supernatants. (E) Schematic depiction of the assay and representative western blot analysis. (F) Image-based quantification of the CCL21-ΔC band intensity from western blots as in E. A.U., arbitrary units, as produced by the western blot imager (G) ELISA-based quantification of total CCL21, performed with antibody clone AF457. Pooled data from n = 6–7 mice/condition, with one CHS-inflamed and a contralateral CTR ear, are shown in E and F. Data from the same mouse are connected by a line. The mean is shown in red, paired Student’s t test. (H–J) Transwell chemotaxis assays were performed on elution assay supernatants (see E) with 1:1 mixtures of LPS-matured labelled WT and CCR7 −/− DCs in presence/absence of a CCL21-blocking antibody. Flow cytometry–based quantification of the total numbers of transmigrated (H) WT DCs and (I) CCR7 −/− DCs, as well as of (J) the ratio of transmigrated WT to CCR7 −/− DCs. Data points from 3–7 experiments per condition are shown. Mixed effects statistical analysis. (K) Ratio of WT: CCR7 −/− DCs measured in seven paired experiments performed for CTR and CHS-inflamed condition. Statistical analysis: paired Student's t test. (L and M) Western blot analysis of protein extracts of (L) steady-state human skin (CTR) and (M) donor-matched steady-state (CTR) and inflamed (INF) human skin from a psoriasis patient. Data from one out of two experiments in L and one experiment in M are shown. Recombinant human full-length CCL21 was loaded as a CTR. Source data are available for this figure: .
    Recombinant Murine Plasmin, supplied by Innovative Research Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant murine plasmin/product/Innovative Research Inc
    Average 94 stars, based on 1 article reviews
    recombinant murine plasmin - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    94
    Sino Biological human recombinant ccl21 protein
    A soluble proteoform of CCL21 (CCL21-ΔC) with chemotactic activity is present in murine skin and increased in CHS-inflamed skin. (A) Representative western blot of CCL21 performed on steady-state (CTR) and CHS-inflamed (CHS) murine ear skin protein extracts. <t>Recombinant</t> CCL21 was loaded as a CTR. (B) Western blot analysis of recombinant human full-length CCL21 and CCL21-ΔC protein. One out of two experiments is shown. (C) Quantification of the full-length CCL21 (gray) and CCL21-ΔC (white) relative band percentages. Pooled data from n = 4 independent biological replicates. (D) ELISA-based quantification of total CCL21 in tissue protein extracts, performed with antibody clone AF457, which detects full-length CCL21 and CCL21-ΔC. Pooled data from n = 5 mice/condition. Statistics: unpaired Student’s t test. (E–J) Skin elution assay and analyses were performed on the supernatants. (E) Schematic depiction of the assay and representative western blot analysis. (F) Image-based quantification of the CCL21-ΔC band intensity from western blots as in E. A.U., arbitrary units, as produced by the western blot imager (G) ELISA-based quantification of total CCL21, performed with antibody clone AF457. Pooled data from n = 6–7 mice/condition, with one CHS-inflamed and a contralateral CTR ear, are shown in E and F. Data from the same mouse are connected by a line. The mean is shown in red, paired Student’s t test. (H–J) Transwell chemotaxis assays were performed on elution assay supernatants (see E) with 1:1 mixtures of LPS-matured labelled WT and CCR7 −/− DCs in presence/absence of a CCL21-blocking antibody. Flow cytometry–based quantification of the total numbers of transmigrated (H) WT DCs and (I) CCR7 −/− DCs, as well as of (J) the ratio of transmigrated WT to CCR7 −/− DCs. Data points from 3–7 experiments per condition are shown. Mixed effects statistical analysis. (K) Ratio of WT: CCR7 −/− DCs measured in seven paired experiments performed for CTR and CHS-inflamed condition. Statistical analysis: paired Student's t test. (L and M) Western blot analysis of protein extracts of (L) steady-state human skin (CTR) and (M) donor-matched steady-state (CTR) and inflamed (INF) human skin from a psoriasis patient. Data from one out of two experiments in L and one experiment in M are shown. Recombinant human full-length CCL21 was loaded as a CTR. Source data are available for this figure: .
    Human Recombinant Ccl21 Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human recombinant ccl21 protein/product/Sino Biological
    Average 94 stars, based on 1 article reviews
    human recombinant ccl21 protein - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    90
    PeproTech human recombinant ccl21
    A soluble proteoform of CCL21 (CCL21-ΔC) with chemotactic activity is present in murine skin and increased in CHS-inflamed skin. (A) Representative western blot of CCL21 performed on steady-state (CTR) and CHS-inflamed (CHS) murine ear skin protein extracts. <t>Recombinant</t> CCL21 was loaded as a CTR. (B) Western blot analysis of recombinant human full-length CCL21 and CCL21-ΔC protein. One out of two experiments is shown. (C) Quantification of the full-length CCL21 (gray) and CCL21-ΔC (white) relative band percentages. Pooled data from n = 4 independent biological replicates. (D) ELISA-based quantification of total CCL21 in tissue protein extracts, performed with antibody clone AF457, which detects full-length CCL21 and CCL21-ΔC. Pooled data from n = 5 mice/condition. Statistics: unpaired Student’s t test. (E–J) Skin elution assay and analyses were performed on the supernatants. (E) Schematic depiction of the assay and representative western blot analysis. (F) Image-based quantification of the CCL21-ΔC band intensity from western blots as in E. A.U., arbitrary units, as produced by the western blot imager (G) ELISA-based quantification of total CCL21, performed with antibody clone AF457. Pooled data from n = 6–7 mice/condition, with one CHS-inflamed and a contralateral CTR ear, are shown in E and F. Data from the same mouse are connected by a line. The mean is shown in red, paired Student’s t test. (H–J) Transwell chemotaxis assays were performed on elution assay supernatants (see E) with 1:1 mixtures of LPS-matured labelled WT and CCR7 −/− DCs in presence/absence of a CCL21-blocking antibody. Flow cytometry–based quantification of the total numbers of transmigrated (H) WT DCs and (I) CCR7 −/− DCs, as well as of (J) the ratio of transmigrated WT to CCR7 −/− DCs. Data points from 3–7 experiments per condition are shown. Mixed effects statistical analysis. (K) Ratio of WT: CCR7 −/− DCs measured in seven paired experiments performed for CTR and CHS-inflamed condition. Statistical analysis: paired Student's t test. (L and M) Western blot analysis of protein extracts of (L) steady-state human skin (CTR) and (M) donor-matched steady-state (CTR) and inflamed (INF) human skin from a psoriasis patient. Data from one out of two experiments in L and one experiment in M are shown. Recombinant human full-length CCL21 was loaded as a CTR. Source data are available for this figure: .
    Human Recombinant Ccl21, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human recombinant ccl21/product/PeproTech
    Average 90 stars, based on 1 article reviews
    human recombinant ccl21 - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    PeproTech ccl21 recombinant human
    (a-c) Naïve T cells were cultured on chip with IL-7. Representative image (b) and quantification (c) of T cell viability after 4 days, labeled with (Calcein AM, green, and Dapi, blue) for 3 donors. (d-g) A <t>CCL21</t> gradient was established on chip, with CCL21 added to the left-hand media lane. Representative images (e) and quantification (f) of naive CD4+ T cells after migrating toward CCL21 for 1 hr and staining with Calcein AM (green). (g) Quantification of cell velocity 30 min after gradient set up (cells were unlabeled). (h-k) Naïve T cells were cultured without (i) and with (ii) a-CD3/CD28 (StemCell). Images of CD69+ signal (FITC-anti-CD69, green) for (i) naïve and (ii) activated T cells on-chip, and quantification (j) of CD69 signal after 48 hours (unpaired T test, **:p<0.005). (k) Quantification of IFN-γ secretion by activated or naïve CD4+T cells on-chip measured by ELISA of supernatants collected at day 5. Panels f, g, k analyzed with ordinary two-way ANOVA with Sidak’s multiple comparisons test w/single pooled variance, ns: p>0.05, *:p<0.05, ****:p<0.00005.
    Ccl21 Recombinant Human, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ccl21 recombinant human/product/PeproTech
    Average 90 stars, based on 1 article reviews
    ccl21 recombinant human - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    PeproTech human recombinant ccl21 200 ng/ml
    Monocyte-derived DCs (Mo-DCs) were treated (or not) with HIF1A inhibitor PX-478 (PX) or LDH inhibitor oxamate (OX) and stimulated with iMtb for 24 hr. ( A ) Lactate release as measured in supernatants in DCs stimulated or not with iMtb in the presence of OX (N = 5). ( B ) Percentage of migrated cells toward <t>CCL21</t> relative to the number of initial cells per condition (N = 6). ( C, D ) Three-dimensional amoeboid migration of DCs through a collagen matrix after 24 hr. Cells within the matrix were fixed and stained with DAPI. Images of the membrane of each insert were taken and the percentage of cells per field were counted. ( C ) Mo-DCs stimulated with iMtb for 24 hr (N = 5). ( D ) Mo-DCs infected with Mtb for 24 hr (N = 4). The data are represented as scatter plots, where each circle represents a microphotograph sourced from either five ( C ) or four ( D ) independent donors, with each experiment typically including between 5 to 10 microphotographs. ( E ) Representative schematic of the experimental setup for in vivo migration assays. ( F ) Percentages of migrating bone marrow-derived DCs (BMDCs) (CFSE-labeled among CD11c + ) recovered from inguinal lymph nodes (N = 3). Statistical significance assessed by ( A, B ) ANOVA followed by Dunnett’s multiple-comparisons test (*p<0.05; **p<0.01); ( C, D ) Nested ANOVA followed by Dunnett’s multiple-comparisons test (*p<0.05; **p<0.01); ( F ) ANOVA followed by Holm–Sidak’s multiple-comparisons test (*p<0.05).
    Human Recombinant Ccl21 200 Ng/Ml, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human recombinant ccl21 200 ng/ml/product/PeproTech
    Average 90 stars, based on 1 article reviews
    human recombinant ccl21 200 ng/ml - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    PeproTech recombinant human exodus-2 (ccl21)
    Monocyte-derived DCs (Mo-DCs) were treated (or not) with HIF1A inhibitor PX-478 (PX) or LDH inhibitor oxamate (OX) and stimulated with iMtb for 24 hr. ( A ) Lactate release as measured in supernatants in DCs stimulated or not with iMtb in the presence of OX (N = 5). ( B ) Percentage of migrated cells toward <t>CCL21</t> relative to the number of initial cells per condition (N = 6). ( C, D ) Three-dimensional amoeboid migration of DCs through a collagen matrix after 24 hr. Cells within the matrix were fixed and stained with DAPI. Images of the membrane of each insert were taken and the percentage of cells per field were counted. ( C ) Mo-DCs stimulated with iMtb for 24 hr (N = 5). ( D ) Mo-DCs infected with Mtb for 24 hr (N = 4). The data are represented as scatter plots, where each circle represents a microphotograph sourced from either five ( C ) or four ( D ) independent donors, with each experiment typically including between 5 to 10 microphotographs. ( E ) Representative schematic of the experimental setup for in vivo migration assays. ( F ) Percentages of migrating bone marrow-derived DCs (BMDCs) (CFSE-labeled among CD11c + ) recovered from inguinal lymph nodes (N = 3). Statistical significance assessed by ( A, B ) ANOVA followed by Dunnett’s multiple-comparisons test (*p<0.05; **p<0.01); ( C, D ) Nested ANOVA followed by Dunnett’s multiple-comparisons test (*p<0.05; **p<0.01); ( F ) ANOVA followed by Holm–Sidak’s multiple-comparisons test (*p<0.05).
    Recombinant Human Exodus 2 (Ccl21), supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human exodus-2 (ccl21)/product/PeproTech
    Average 90 stars, based on 1 article reviews
    recombinant human exodus-2 (ccl21) - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    93
    R&D Systems ccl21 recombinant protein
    Monocyte-derived DCs (Mo-DCs) were treated (or not) with HIF1A inhibitor PX-478 (PX) or LDH inhibitor oxamate (OX) and stimulated with iMtb for 24 hr. ( A ) Lactate release as measured in supernatants in DCs stimulated or not with iMtb in the presence of OX (N = 5). ( B ) Percentage of migrated cells toward <t>CCL21</t> relative to the number of initial cells per condition (N = 6). ( C, D ) Three-dimensional amoeboid migration of DCs through a collagen matrix after 24 hr. Cells within the matrix were fixed and stained with DAPI. Images of the membrane of each insert were taken and the percentage of cells per field were counted. ( C ) Mo-DCs stimulated with iMtb for 24 hr (N = 5). ( D ) Mo-DCs infected with Mtb for 24 hr (N = 4). The data are represented as scatter plots, where each circle represents a microphotograph sourced from either five ( C ) or four ( D ) independent donors, with each experiment typically including between 5 to 10 microphotographs. ( E ) Representative schematic of the experimental setup for in vivo migration assays. ( F ) Percentages of migrating bone marrow-derived DCs (BMDCs) (CFSE-labeled among CD11c + ) recovered from inguinal lymph nodes (N = 3). Statistical significance assessed by ( A, B ) ANOVA followed by Dunnett’s multiple-comparisons test (*p<0.05; **p<0.01); ( C, D ) Nested ANOVA followed by Dunnett’s multiple-comparisons test (*p<0.05; **p<0.01); ( F ) ANOVA followed by Holm–Sidak’s multiple-comparisons test (*p<0.05).
    Ccl21 Recombinant Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ccl21 recombinant protein/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    ccl21 recombinant protein - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    90
    PeproTech recombinant human ccl21
    Association between <t>CCL21</t> levels and immunotherapy response in HCC. A Transcriptome analysis showed that CCL21 was upregulated in responders. B Serum CCL21 levels of responders and non-responders in the training cohort. C Using the median serum CCL21 concentration (1736 pg/ml) as the cutoff value, the proportion of responders and non-responders in different serum CCL21 levels. D Serum CCL21 levels of responders and non-responders in the validation cohort. E Using the median serum CCL21 concentration of training cohort as the cutoff value, the proportion of responders and non-responders in different serum CCL21 levels. F ROC curve analysis of predictive performance of high serum CCL21 level for predicting immunotherapy response in training and validation cohorts. One-way ANOVA with a post hoc LSD test. Categorical variables were presented as n (%) and constituent ratio between groups was compared using Pearson χ 2 and Fisher’s exact test. HCC, hepatocellular carcinoma; CCL21, Chemokine C–C motif ligand 21; ROC curve analysis, receiver operating characteristic curve analysis
    Recombinant Human Ccl21, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human ccl21/product/PeproTech
    Average 90 stars, based on 1 article reviews
    recombinant human ccl21 - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    Image Search Results


    A soluble proteoform of CCL21 (CCL21-ΔC) with chemotactic activity is present in murine skin and increased in CHS-inflamed skin. (A) Representative western blot of CCL21 performed on steady-state (CTR) and CHS-inflamed (CHS) murine ear skin protein extracts. Recombinant CCL21 was loaded as a CTR. (B) Western blot analysis of recombinant human full-length CCL21 and CCL21-ΔC protein. One out of two experiments is shown. (C) Quantification of the full-length CCL21 (gray) and CCL21-ΔC (white) relative band percentages. Pooled data from n = 4 independent biological replicates. (D) ELISA-based quantification of total CCL21 in tissue protein extracts, performed with antibody clone AF457, which detects full-length CCL21 and CCL21-ΔC. Pooled data from n = 5 mice/condition. Statistics: unpaired Student’s t test. (E–J) Skin elution assay and analyses were performed on the supernatants. (E) Schematic depiction of the assay and representative western blot analysis. (F) Image-based quantification of the CCL21-ΔC band intensity from western blots as in E. A.U., arbitrary units, as produced by the western blot imager (G) ELISA-based quantification of total CCL21, performed with antibody clone AF457. Pooled data from n = 6–7 mice/condition, with one CHS-inflamed and a contralateral CTR ear, are shown in E and F. Data from the same mouse are connected by a line. The mean is shown in red, paired Student’s t test. (H–J) Transwell chemotaxis assays were performed on elution assay supernatants (see E) with 1:1 mixtures of LPS-matured labelled WT and CCR7 −/− DCs in presence/absence of a CCL21-blocking antibody. Flow cytometry–based quantification of the total numbers of transmigrated (H) WT DCs and (I) CCR7 −/− DCs, as well as of (J) the ratio of transmigrated WT to CCR7 −/− DCs. Data points from 3–7 experiments per condition are shown. Mixed effects statistical analysis. (K) Ratio of WT: CCR7 −/− DCs measured in seven paired experiments performed for CTR and CHS-inflamed condition. Statistical analysis: paired Student's t test. (L and M) Western blot analysis of protein extracts of (L) steady-state human skin (CTR) and (M) donor-matched steady-state (CTR) and inflamed (INF) human skin from a psoriasis patient. Data from one out of two experiments in L and one experiment in M are shown. Recombinant human full-length CCL21 was loaded as a CTR. Source data are available for this figure: .

    Journal: The Journal of Cell Biology

    Article Title: uPA-mediated remodeling of CCL21 gradients regulates lymphatic migration of dendritic cells

    doi: 10.1083/jcb.202412190

    Figure Lengend Snippet: A soluble proteoform of CCL21 (CCL21-ΔC) with chemotactic activity is present in murine skin and increased in CHS-inflamed skin. (A) Representative western blot of CCL21 performed on steady-state (CTR) and CHS-inflamed (CHS) murine ear skin protein extracts. Recombinant CCL21 was loaded as a CTR. (B) Western blot analysis of recombinant human full-length CCL21 and CCL21-ΔC protein. One out of two experiments is shown. (C) Quantification of the full-length CCL21 (gray) and CCL21-ΔC (white) relative band percentages. Pooled data from n = 4 independent biological replicates. (D) ELISA-based quantification of total CCL21 in tissue protein extracts, performed with antibody clone AF457, which detects full-length CCL21 and CCL21-ΔC. Pooled data from n = 5 mice/condition. Statistics: unpaired Student’s t test. (E–J) Skin elution assay and analyses were performed on the supernatants. (E) Schematic depiction of the assay and representative western blot analysis. (F) Image-based quantification of the CCL21-ΔC band intensity from western blots as in E. A.U., arbitrary units, as produced by the western blot imager (G) ELISA-based quantification of total CCL21, performed with antibody clone AF457. Pooled data from n = 6–7 mice/condition, with one CHS-inflamed and a contralateral CTR ear, are shown in E and F. Data from the same mouse are connected by a line. The mean is shown in red, paired Student’s t test. (H–J) Transwell chemotaxis assays were performed on elution assay supernatants (see E) with 1:1 mixtures of LPS-matured labelled WT and CCR7 −/− DCs in presence/absence of a CCL21-blocking antibody. Flow cytometry–based quantification of the total numbers of transmigrated (H) WT DCs and (I) CCR7 −/− DCs, as well as of (J) the ratio of transmigrated WT to CCR7 −/− DCs. Data points from 3–7 experiments per condition are shown. Mixed effects statistical analysis. (K) Ratio of WT: CCR7 −/− DCs measured in seven paired experiments performed for CTR and CHS-inflamed condition. Statistical analysis: paired Student's t test. (L and M) Western blot analysis of protein extracts of (L) steady-state human skin (CTR) and (M) donor-matched steady-state (CTR) and inflamed (INF) human skin from a psoriasis patient. Data from one out of two experiments in L and one experiment in M are shown. Recombinant human full-length CCL21 was loaded as a CTR. Source data are available for this figure: .

    Article Snippet: Murine recombinant CCL21 (#250-13; PeproTech) and recombinant murine plasmin (Molecular Innovations) at molar ratios of CCL21 to plasmin of 1:0.02–1:0.16 (starting with 100 nM CCL21 and 2 nM plasmin) were incubated in PBS or serum-free ProCHO medium (Lonza) for 4 h at 37°C.

    Techniques: Activity Assay, Western Blot, Recombinant, Enzyme-linked Immunosorbent Assay, Produced, Chemotaxis Assay, Blocking Assay, Flow Cytometry

    In vitro assays demonstrating CCL21 cleavage by plasmin. (A and B) Western blot analysis of (A) human and (B) murine CCL21 cleavage after incubation with recombinant plasmin with a fixed molar ratio of 1:0.08 for increasing times at 37°C, as indicated in the figure. (C) Dose titration of the plasmin inhibitor C3 to a fixed molar ratio of murine CCL21:plasmin (1:0.08) and incubation for up to 4 h, as indicated in the figure. Representative western blots of n = 2 (A) or n = 3 (B and C) experiments are shown. (D) Fluorometric plasmin activation assay, with indicated plasmin (12 μM) and inhibitor concentrations. The % increase from T 0 (0 min) is depicted. PIC: broad spectrum protease inhibitor. Representative results of n = 3 independent experiments are shown. Source data are available for this figure: .

    Journal: The Journal of Cell Biology

    Article Title: uPA-mediated remodeling of CCL21 gradients regulates lymphatic migration of dendritic cells

    doi: 10.1083/jcb.202412190

    Figure Lengend Snippet: In vitro assays demonstrating CCL21 cleavage by plasmin. (A and B) Western blot analysis of (A) human and (B) murine CCL21 cleavage after incubation with recombinant plasmin with a fixed molar ratio of 1:0.08 for increasing times at 37°C, as indicated in the figure. (C) Dose titration of the plasmin inhibitor C3 to a fixed molar ratio of murine CCL21:plasmin (1:0.08) and incubation for up to 4 h, as indicated in the figure. Representative western blots of n = 2 (A) or n = 3 (B and C) experiments are shown. (D) Fluorometric plasmin activation assay, with indicated plasmin (12 μM) and inhibitor concentrations. The % increase from T 0 (0 min) is depicted. PIC: broad spectrum protease inhibitor. Representative results of n = 3 independent experiments are shown. Source data are available for this figure: .

    Article Snippet: Murine recombinant CCL21 (#250-13; PeproTech) and recombinant murine plasmin (Molecular Innovations) at molar ratios of CCL21 to plasmin of 1:0.02–1:0.16 (starting with 100 nM CCL21 and 2 nM plasmin) were incubated in PBS or serum-free ProCHO medium (Lonza) for 4 h at 37°C.

    Techniques: In Vitro, Western Blot, Incubation, Recombinant, Titration, Activation Assay, Protease Inhibitor

    LECs activate plasminogen to plasmin, thereby generating CCL21-ΔC with enhanced chemotactic activity. (A and B) Quantification of (A) plasminogen and (B) plasmin activity in tissue protein extracts generated from CTR or CHS-inflamed ear skin. n = 6–7 mice per condition. (C) CTR experiment with CHS-inflamed ears documenting that the plasmin activity observed in C can be completely blocked in presence of the plasmin inhibitor C3. (D) Schematic depiction of the experimental hypothesis: Inflammation leads to enhanced extravasation of plasminogen. uPA bound to uPAR on CCL21-secreting LECs converts plasminogen to plasmin, thereby inducing CCL21 cleavage into CCL21-ΔC. (E–G) In vitro CCL21 cleavage experiment: (E) Schematic depiction of the experiment: immortalized LECs were incubated with recombinant CCL21 (100 nM) and plasminogen (20 nM) for 4 h or 24 h at 37°C in absence or presence of the plasmin inhibitor C3, mU1, or PIC. Supernatants were analyzed by western blot for CCL21. (F) Representative western blot of the cell culture supernatant at indicated time points and conditions and (G) quantification of the full-length CCL21 (gray) and CCL21-ΔC (white) relative band percentage. Pooled data from n = 4 independent experiments. Mean ± SEM, one-way ANOVA, and P values are relative to the “plg only” condition. (H and I) Cell culture supernatants generated as in E were evaluated in a 3D collagen migration assay. Recombinant human CCL21 and CCL21-ΔC were used as positive CTRs (H) Cell trajectory plots of migrating BMDCs’ migratory tracks in response to the stimuli applied on either side of the collagen channel. (I) Quantification of DC directionality, displacement, and velocity in response to the stimuli applied. Pooled data from n = 2 independent experiments with a total of n = 40–50 tracks analyzed per condition. Mean ± SEM, unpaired Student's t test for each comparison. (J–L) Analysis of the CCL21 cleavage activity of LECs isolated from uPA −/− mice or mice with defective uPA binding to uPAR (uPA mut ) (J) Schematic illustration of the three genotypes investigated. (K and L) Representative western blot of the cell culture supernatants after (K) 4 h and (L) 24 h of incubation (top) and quantification of the full-length CCL21 (gray) and CCL21-ΔC (white) relative band percentage (bottom). Pooled data from n = 5 independent experiments. Mean ± SEM, one-way ANOVA, and Source data are available for this figure: . plg, plasminogen.

    Journal: The Journal of Cell Biology

    Article Title: uPA-mediated remodeling of CCL21 gradients regulates lymphatic migration of dendritic cells

    doi: 10.1083/jcb.202412190

    Figure Lengend Snippet: LECs activate plasminogen to plasmin, thereby generating CCL21-ΔC with enhanced chemotactic activity. (A and B) Quantification of (A) plasminogen and (B) plasmin activity in tissue protein extracts generated from CTR or CHS-inflamed ear skin. n = 6–7 mice per condition. (C) CTR experiment with CHS-inflamed ears documenting that the plasmin activity observed in C can be completely blocked in presence of the plasmin inhibitor C3. (D) Schematic depiction of the experimental hypothesis: Inflammation leads to enhanced extravasation of plasminogen. uPA bound to uPAR on CCL21-secreting LECs converts plasminogen to plasmin, thereby inducing CCL21 cleavage into CCL21-ΔC. (E–G) In vitro CCL21 cleavage experiment: (E) Schematic depiction of the experiment: immortalized LECs were incubated with recombinant CCL21 (100 nM) and plasminogen (20 nM) for 4 h or 24 h at 37°C in absence or presence of the plasmin inhibitor C3, mU1, or PIC. Supernatants were analyzed by western blot for CCL21. (F) Representative western blot of the cell culture supernatant at indicated time points and conditions and (G) quantification of the full-length CCL21 (gray) and CCL21-ΔC (white) relative band percentage. Pooled data from n = 4 independent experiments. Mean ± SEM, one-way ANOVA, and P values are relative to the “plg only” condition. (H and I) Cell culture supernatants generated as in E were evaluated in a 3D collagen migration assay. Recombinant human CCL21 and CCL21-ΔC were used as positive CTRs (H) Cell trajectory plots of migrating BMDCs’ migratory tracks in response to the stimuli applied on either side of the collagen channel. (I) Quantification of DC directionality, displacement, and velocity in response to the stimuli applied. Pooled data from n = 2 independent experiments with a total of n = 40–50 tracks analyzed per condition. Mean ± SEM, unpaired Student's t test for each comparison. (J–L) Analysis of the CCL21 cleavage activity of LECs isolated from uPA −/− mice or mice with defective uPA binding to uPAR (uPA mut ) (J) Schematic illustration of the three genotypes investigated. (K and L) Representative western blot of the cell culture supernatants after (K) 4 h and (L) 24 h of incubation (top) and quantification of the full-length CCL21 (gray) and CCL21-ΔC (white) relative band percentage (bottom). Pooled data from n = 5 independent experiments. Mean ± SEM, one-way ANOVA, and Source data are available for this figure: . plg, plasminogen.

    Article Snippet: Murine recombinant CCL21 (#250-13; PeproTech) and recombinant murine plasmin (Molecular Innovations) at molar ratios of CCL21 to plasmin of 1:0.02–1:0.16 (starting with 100 nM CCL21 and 2 nM plasmin) were incubated in PBS or serum-free ProCHO medium (Lonza) for 4 h at 37°C.

    Techniques: Activity Assay, Generated, In Vitro, Incubation, Recombinant, Western Blot, Cell Culture, Migration, Comparison, Isolation, Binding Assay

    Video showing fluorescently labeled bone marrow–derived DCs (green) moving in 3D collagen toward recombinant human CCL21 (up) and CCL21+plg (down) provided in reservoirs on left and right, respectively, of the chamber. WT DCs display enhanced migration toward CCL21-ΔC provided on the left. Video specifications: 5-min intervals; 5 frames/s (1500-fold accelerated). The original length of the recording: 200 min. Video length: 8 s. plg, plasminogen.

    Journal: The Journal of Cell Biology

    Article Title: uPA-mediated remodeling of CCL21 gradients regulates lymphatic migration of dendritic cells

    doi: 10.1083/jcb.202412190

    Figure Lengend Snippet: Video showing fluorescently labeled bone marrow–derived DCs (green) moving in 3D collagen toward recombinant human CCL21 (up) and CCL21+plg (down) provided in reservoirs on left and right, respectively, of the chamber. WT DCs display enhanced migration toward CCL21-ΔC provided on the left. Video specifications: 5-min intervals; 5 frames/s (1500-fold accelerated). The original length of the recording: 200 min. Video length: 8 s. plg, plasminogen.

    Article Snippet: Murine recombinant CCL21 (#250-13; PeproTech) and recombinant murine plasmin (Molecular Innovations) at molar ratios of CCL21 to plasmin of 1:0.02–1:0.16 (starting with 100 nM CCL21 and 2 nM plasmin) were incubated in PBS or serum-free ProCHO medium (Lonza) for 4 h at 37°C.

    Techniques: Labeling, Derivative Assay, Recombinant, Migration

    (a-c) Naïve T cells were cultured on chip with IL-7. Representative image (b) and quantification (c) of T cell viability after 4 days, labeled with (Calcein AM, green, and Dapi, blue) for 3 donors. (d-g) A CCL21 gradient was established on chip, with CCL21 added to the left-hand media lane. Representative images (e) and quantification (f) of naive CD4+ T cells after migrating toward CCL21 for 1 hr and staining with Calcein AM (green). (g) Quantification of cell velocity 30 min after gradient set up (cells were unlabeled). (h-k) Naïve T cells were cultured without (i) and with (ii) a-CD3/CD28 (StemCell). Images of CD69+ signal (FITC-anti-CD69, green) for (i) naïve and (ii) activated T cells on-chip, and quantification (j) of CD69 signal after 48 hours (unpaired T test, **:p<0.005). (k) Quantification of IFN-γ secretion by activated or naïve CD4+T cells on-chip measured by ELISA of supernatants collected at day 5. Panels f, g, k analyzed with ordinary two-way ANOVA with Sidak’s multiple comparisons test w/single pooled variance, ns: p>0.05, *:p<0.05, ****:p<0.00005.

    Journal: bioRxiv

    Article Title: Initiation of primary T cell—B cell interactions and extrafollicular antibody responses in an organized microphysiological model of the human lymph node

    doi: 10.1101/2025.01.12.632545

    Figure Lengend Snippet: (a-c) Naïve T cells were cultured on chip with IL-7. Representative image (b) and quantification (c) of T cell viability after 4 days, labeled with (Calcein AM, green, and Dapi, blue) for 3 donors. (d-g) A CCL21 gradient was established on chip, with CCL21 added to the left-hand media lane. Representative images (e) and quantification (f) of naive CD4+ T cells after migrating toward CCL21 for 1 hr and staining with Calcein AM (green). (g) Quantification of cell velocity 30 min after gradient set up (cells were unlabeled). (h-k) Naïve T cells were cultured without (i) and with (ii) a-CD3/CD28 (StemCell). Images of CD69+ signal (FITC-anti-CD69, green) for (i) naïve and (ii) activated T cells on-chip, and quantification (j) of CD69 signal after 48 hours (unpaired T test, **:p<0.005). (k) Quantification of IFN-γ secretion by activated or naïve CD4+T cells on-chip measured by ELISA of supernatants collected at day 5. Panels f, g, k analyzed with ordinary two-way ANOVA with Sidak’s multiple comparisons test w/single pooled variance, ns: p>0.05, *:p<0.05, ****:p<0.00005.

    Article Snippet: For assessing chemotactic activity of naïve CD4+ T cells on chip, a solution of 0.1 μM CCL21 (recombinant human, Peprotech, NJ, USA, Cat# 300–35A) in AIMV media was added to the left media reservoir.

    Techniques: Cell Culture, Labeling, Staining, Enzyme-linked Immunosorbent Assay

    Monocyte-derived DCs (Mo-DCs) were treated (or not) with HIF1A inhibitor PX-478 (PX) or LDH inhibitor oxamate (OX) and stimulated with iMtb for 24 hr. ( A ) Lactate release as measured in supernatants in DCs stimulated or not with iMtb in the presence of OX (N = 5). ( B ) Percentage of migrated cells toward CCL21 relative to the number of initial cells per condition (N = 6). ( C, D ) Three-dimensional amoeboid migration of DCs through a collagen matrix after 24 hr. Cells within the matrix were fixed and stained with DAPI. Images of the membrane of each insert were taken and the percentage of cells per field were counted. ( C ) Mo-DCs stimulated with iMtb for 24 hr (N = 5). ( D ) Mo-DCs infected with Mtb for 24 hr (N = 4). The data are represented as scatter plots, where each circle represents a microphotograph sourced from either five ( C ) or four ( D ) independent donors, with each experiment typically including between 5 to 10 microphotographs. ( E ) Representative schematic of the experimental setup for in vivo migration assays. ( F ) Percentages of migrating bone marrow-derived DCs (BMDCs) (CFSE-labeled among CD11c + ) recovered from inguinal lymph nodes (N = 3). Statistical significance assessed by ( A, B ) ANOVA followed by Dunnett’s multiple-comparisons test (*p<0.05; **p<0.01); ( C, D ) Nested ANOVA followed by Dunnett’s multiple-comparisons test (*p<0.05; **p<0.01); ( F ) ANOVA followed by Holm–Sidak’s multiple-comparisons test (*p<0.05).

    Journal: eLife

    Article Title: Elevated glycolytic metabolism of monocytes limits the generation of HIF1A-driven migratory dendritic cells in tuberculosis

    doi: 10.7554/eLife.89319

    Figure Lengend Snippet: Monocyte-derived DCs (Mo-DCs) were treated (or not) with HIF1A inhibitor PX-478 (PX) or LDH inhibitor oxamate (OX) and stimulated with iMtb for 24 hr. ( A ) Lactate release as measured in supernatants in DCs stimulated or not with iMtb in the presence of OX (N = 5). ( B ) Percentage of migrated cells toward CCL21 relative to the number of initial cells per condition (N = 6). ( C, D ) Three-dimensional amoeboid migration of DCs through a collagen matrix after 24 hr. Cells within the matrix were fixed and stained with DAPI. Images of the membrane of each insert were taken and the percentage of cells per field were counted. ( C ) Mo-DCs stimulated with iMtb for 24 hr (N = 5). ( D ) Mo-DCs infected with Mtb for 24 hr (N = 4). The data are represented as scatter plots, where each circle represents a microphotograph sourced from either five ( C ) or four ( D ) independent donors, with each experiment typically including between 5 to 10 microphotographs. ( E ) Representative schematic of the experimental setup for in vivo migration assays. ( F ) Percentages of migrating bone marrow-derived DCs (BMDCs) (CFSE-labeled among CD11c + ) recovered from inguinal lymph nodes (N = 3). Statistical significance assessed by ( A, B ) ANOVA followed by Dunnett’s multiple-comparisons test (*p<0.05; **p<0.01); ( C, D ) Nested ANOVA followed by Dunnett’s multiple-comparisons test (*p<0.05; **p<0.01); ( F ) ANOVA followed by Holm–Sidak’s multiple-comparisons test (*p<0.05).

    Article Snippet: Each DC population (4 × 10 5 cells in 75 μl) was placed on the upper chamber of a transwell insert (5 μm pore size, 96-well plate; Corning), and 230 μl of media (RPMI with 0.5% FCS) with human recombinant CCL21 (200 ng/ml) (Peprotech) was placed in the lower chamber.

    Techniques: Derivative Assay, Migration, Staining, Membrane, Infection, In Vivo, Labeling

    ( A, B ) Monocyte-derived DCs (Mo-DCs) were treated or not with the glycolysis inhibitor GSK2837808A and stimulated with iMtb. ( A ) Lactate release (N = 5). ( B ) Chemotactic activity toward CCL21 (N = 5). ( C, D ) Murine bone marrow-derived DCs (BMDCs) were treated or not with PX-478 or oxamate and stimulated with iMtb for 24 hr. ( C ) Lactate release (N = 3). ( D ) Representative dot blots showing the percentages of migrating BMDCs (CD11c + , CFSE-labeled) determined from inguinal lymph nodes. ( E ) Mo-DCs were stimulated with iMtb in the presence of either PX-478 or oxamate and CCR7 expression was measured by FACS (N = 6). Two-way ANOVA followed by Tukey’s multiple-comparisons test (*p<0.05; **p<0.01; ***p<0.001), as depicted by lines. The data are represented as scatter plots, with each circle representing a single individual, means ± SEM are shown.

    Journal: eLife

    Article Title: Elevated glycolytic metabolism of monocytes limits the generation of HIF1A-driven migratory dendritic cells in tuberculosis

    doi: 10.7554/eLife.89319

    Figure Lengend Snippet: ( A, B ) Monocyte-derived DCs (Mo-DCs) were treated or not with the glycolysis inhibitor GSK2837808A and stimulated with iMtb. ( A ) Lactate release (N = 5). ( B ) Chemotactic activity toward CCL21 (N = 5). ( C, D ) Murine bone marrow-derived DCs (BMDCs) were treated or not with PX-478 or oxamate and stimulated with iMtb for 24 hr. ( C ) Lactate release (N = 3). ( D ) Representative dot blots showing the percentages of migrating BMDCs (CD11c + , CFSE-labeled) determined from inguinal lymph nodes. ( E ) Mo-DCs were stimulated with iMtb in the presence of either PX-478 or oxamate and CCR7 expression was measured by FACS (N = 6). Two-way ANOVA followed by Tukey’s multiple-comparisons test (*p<0.05; **p<0.01; ***p<0.001), as depicted by lines. The data are represented as scatter plots, with each circle representing a single individual, means ± SEM are shown.

    Article Snippet: Each DC population (4 × 10 5 cells in 75 μl) was placed on the upper chamber of a transwell insert (5 μm pore size, 96-well plate; Corning), and 230 μl of media (RPMI with 0.5% FCS) with human recombinant CCL21 (200 ng/ml) (Peprotech) was placed in the lower chamber.

    Techniques: Derivative Assay, Activity Assay, Labeling, Expressing

    Tolerogenic Mo-DCs were generated by dexamethasone (Dx) treatment and were stimulated (or not) with irradiated Mycobacterium tuberculosis (iMtb) in the presence or absence of HIF1A activator dimethyloxalylglycine (DMOG). ( A ) Lactate release and glucose uptake as measured in supernatant (N = 8). ( B ) Mean fluorescence intensity (MFI) of HIF1A. Representative histograms and quantification are shown (N = 6). ( C ) Three-dimensional amoeboid migration of DCs through a collagen matrix. After 24 hr of migration, images of stacks within the matrix were taken every 30 µm. Percentage of migrating cells was defined as cells in the stacks within the matrix relative to total number of cells (N = 6). ( D ) Chemotactic activity toward CCL21 in vitro (N = 6). ( E–H ) Mo-DCs were generated from healthy subjects (HS) or TB patients, and DCs were stimulated (or not) with iMtb. ( E ) Chemotaxis index toward CCL21 (relative to unstimulated DCs) (N = 6). ( F ) Lactate production ratio relative to unstimulated DCs (N = 6). ( G ) Glycolytic capacity assessed by SCENITH (N = 4). ( H ) Chemotactic activity toward CCL21 of Mo-DCs from TB patients stimulated with iMtb and treated or not with DMOG (N = 6). Statistical significance assessed by ( A–D ) two-way ANOVA followed by Tukey’s multiple-comparisons test (*p<0.05; **p<0.01); ( E–G ) unpaired t -test (*p<0.05); ( H ) paired t -test (*p<0.05). The data are represented as scatter plots, with each circle representing a single individual, means ± SEM are shown.

    Journal: eLife

    Article Title: Elevated glycolytic metabolism of monocytes limits the generation of HIF1A-driven migratory dendritic cells in tuberculosis

    doi: 10.7554/eLife.89319

    Figure Lengend Snippet: Tolerogenic Mo-DCs were generated by dexamethasone (Dx) treatment and were stimulated (or not) with irradiated Mycobacterium tuberculosis (iMtb) in the presence or absence of HIF1A activator dimethyloxalylglycine (DMOG). ( A ) Lactate release and glucose uptake as measured in supernatant (N = 8). ( B ) Mean fluorescence intensity (MFI) of HIF1A. Representative histograms and quantification are shown (N = 6). ( C ) Three-dimensional amoeboid migration of DCs through a collagen matrix. After 24 hr of migration, images of stacks within the matrix were taken every 30 µm. Percentage of migrating cells was defined as cells in the stacks within the matrix relative to total number of cells (N = 6). ( D ) Chemotactic activity toward CCL21 in vitro (N = 6). ( E–H ) Mo-DCs were generated from healthy subjects (HS) or TB patients, and DCs were stimulated (or not) with iMtb. ( E ) Chemotaxis index toward CCL21 (relative to unstimulated DCs) (N = 6). ( F ) Lactate production ratio relative to unstimulated DCs (N = 6). ( G ) Glycolytic capacity assessed by SCENITH (N = 4). ( H ) Chemotactic activity toward CCL21 of Mo-DCs from TB patients stimulated with iMtb and treated or not with DMOG (N = 6). Statistical significance assessed by ( A–D ) two-way ANOVA followed by Tukey’s multiple-comparisons test (*p<0.05; **p<0.01); ( E–G ) unpaired t -test (*p<0.05); ( H ) paired t -test (*p<0.05). The data are represented as scatter plots, with each circle representing a single individual, means ± SEM are shown.

    Article Snippet: Each DC population (4 × 10 5 cells in 75 μl) was placed on the upper chamber of a transwell insert (5 μm pore size, 96-well plate; Corning), and 230 μl of media (RPMI with 0.5% FCS) with human recombinant CCL21 (200 ng/ml) (Peprotech) was placed in the lower chamber.

    Techniques: Generated, Irradiation, Fluorescence, Migration, Activity Assay, In Vitro, Chemotaxis Assay

    ( A ) Ex vivo determination of HIF1A expression by monocytes from healthy subjects (HS) or TB patients (TB) for each monocyte subset (CD14 + CD16 - , CD14 + CD16 + , and CD14 dim CD16 + ) (N = 6). ( B, C ) Monocytes from HS were treated with dimethyloxalylglycine (DMOG) during the first 24 hr of differentiation with IL-4/GM-CSF (earlyDMOG) and removed afterward. On day 6 of differentiation, cells were stimulated (or not) with irradiated Mycobacterium tuberculosis (iMtb). ( B ) Monocyte lactate release after 24 hr of DMOG addition (N = 4). ( C ) Chemotactic activity toward CCL21 of DCs (N = 5). Statistical significance was assessed by ( B ) paired t -test (p<0.01); ( C ) two-way ANOVA followed by Tukey’s multiple-comparisons test (*p<0.05). The data are represented as scatter plots, with each circle representing a single individual, means ± SEM are shown.

    Journal: eLife

    Article Title: Elevated glycolytic metabolism of monocytes limits the generation of HIF1A-driven migratory dendritic cells in tuberculosis

    doi: 10.7554/eLife.89319

    Figure Lengend Snippet: ( A ) Ex vivo determination of HIF1A expression by monocytes from healthy subjects (HS) or TB patients (TB) for each monocyte subset (CD14 + CD16 - , CD14 + CD16 + , and CD14 dim CD16 + ) (N = 6). ( B, C ) Monocytes from HS were treated with dimethyloxalylglycine (DMOG) during the first 24 hr of differentiation with IL-4/GM-CSF (earlyDMOG) and removed afterward. On day 6 of differentiation, cells were stimulated (or not) with irradiated Mycobacterium tuberculosis (iMtb). ( B ) Monocyte lactate release after 24 hr of DMOG addition (N = 4). ( C ) Chemotactic activity toward CCL21 of DCs (N = 5). Statistical significance was assessed by ( B ) paired t -test (p<0.01); ( C ) two-way ANOVA followed by Tukey’s multiple-comparisons test (*p<0.05). The data are represented as scatter plots, with each circle representing a single individual, means ± SEM are shown.

    Article Snippet: Each DC population (4 × 10 5 cells in 75 μl) was placed on the upper chamber of a transwell insert (5 μm pore size, 96-well plate; Corning), and 230 μl of media (RPMI with 0.5% FCS) with human recombinant CCL21 (200 ng/ml) (Peprotech) was placed in the lower chamber.

    Techniques: Ex Vivo, Expressing, Irradiation, Activity Assay

    Journal: eLife

    Article Title: Elevated glycolytic metabolism of monocytes limits the generation of HIF1A-driven migratory dendritic cells in tuberculosis

    doi: 10.7554/eLife.89319

    Figure Lengend Snippet:

    Article Snippet: Each DC population (4 × 10 5 cells in 75 μl) was placed on the upper chamber of a transwell insert (5 μm pore size, 96-well plate; Corning), and 230 μl of media (RPMI with 0.5% FCS) with human recombinant CCL21 (200 ng/ml) (Peprotech) was placed in the lower chamber.

    Techniques: Recombinant, Enzyme-linked Immunosorbent Assay, Sequencing, Software

    Monocyte-derived DCs (Mo-DCs) were treated (or not) with HIF1A inhibitor PX-478 (PX) or LDH inhibitor oxamate (OX) and stimulated with iMtb for 24 hr. ( A ) Lactate release as measured in supernatants in DCs stimulated or not with iMtb in the presence of OX (N = 5). ( B ) Percentage of migrated cells toward CCL21 relative to the number of initial cells per condition (N = 6). ( C, D ) Three-dimensional amoeboid migration of DCs through a collagen matrix after 24 hr. Cells within the matrix were fixed and stained with DAPI. Images of the membrane of each insert were taken and the percentage of cells per field were counted. ( C ) Mo-DCs stimulated with iMtb for 24 hr (N = 5). ( D ) Mo-DCs infected with Mtb for 24 hr (N = 4). The data are represented as scatter plots, where each circle represents a microphotograph sourced from either five ( C ) or four ( D ) independent donors, with each experiment typically including between 5 to 10 microphotographs. ( E ) Representative schematic of the experimental setup for in vivo migration assays. ( F ) Percentages of migrating bone marrow-derived DCs (BMDCs) (CFSE-labeled among CD11c + ) recovered from inguinal lymph nodes (N = 3). Statistical significance assessed by ( A, B ) ANOVA followed by Dunnett’s multiple-comparisons test (*p<0.05; **p<0.01); ( C, D ) Nested ANOVA followed by Dunnett’s multiple-comparisons test (*p<0.05; **p<0.01); ( F ) ANOVA followed by Holm–Sidak’s multiple-comparisons test (*p<0.05).

    Journal: eLife

    Article Title: Elevated glycolytic metabolism of monocytes limits the generation of HIF1A-driven migratory dendritic cells in tuberculosis

    doi: 10.7554/eLife.89319

    Figure Lengend Snippet: Monocyte-derived DCs (Mo-DCs) were treated (or not) with HIF1A inhibitor PX-478 (PX) or LDH inhibitor oxamate (OX) and stimulated with iMtb for 24 hr. ( A ) Lactate release as measured in supernatants in DCs stimulated or not with iMtb in the presence of OX (N = 5). ( B ) Percentage of migrated cells toward CCL21 relative to the number of initial cells per condition (N = 6). ( C, D ) Three-dimensional amoeboid migration of DCs through a collagen matrix after 24 hr. Cells within the matrix were fixed and stained with DAPI. Images of the membrane of each insert were taken and the percentage of cells per field were counted. ( C ) Mo-DCs stimulated with iMtb for 24 hr (N = 5). ( D ) Mo-DCs infected with Mtb for 24 hr (N = 4). The data are represented as scatter plots, where each circle represents a microphotograph sourced from either five ( C ) or four ( D ) independent donors, with each experiment typically including between 5 to 10 microphotographs. ( E ) Representative schematic of the experimental setup for in vivo migration assays. ( F ) Percentages of migrating bone marrow-derived DCs (BMDCs) (CFSE-labeled among CD11c + ) recovered from inguinal lymph nodes (N = 3). Statistical significance assessed by ( A, B ) ANOVA followed by Dunnett’s multiple-comparisons test (*p<0.05; **p<0.01); ( C, D ) Nested ANOVA followed by Dunnett’s multiple-comparisons test (*p<0.05; **p<0.01); ( F ) ANOVA followed by Holm–Sidak’s multiple-comparisons test (*p<0.05).

    Article Snippet: Peptide, recombinant protein , Recombinant Human Exodus-2 (CCL21) , Peprotech , Cat# 300-35A , .

    Techniques: Derivative Assay, Migration, Staining, Membrane, Infection, In Vivo, Labeling

    ( A, B ) Monocyte-derived DCs (Mo-DCs) were treated or not with the glycolysis inhibitor GSK2837808A and stimulated with iMtb. ( A ) Lactate release (N = 5). ( B ) Chemotactic activity toward CCL21 (N = 5). ( C, D ) Murine bone marrow-derived DCs (BMDCs) were treated or not with PX-478 or oxamate and stimulated with iMtb for 24 hr. ( C ) Lactate release (N = 3). ( D ) Representative dot blots showing the percentages of migrating BMDCs (CD11c + , CFSE-labeled) determined from inguinal lymph nodes. ( E ) Mo-DCs were stimulated with iMtb in the presence of either PX-478 or oxamate and CCR7 expression was measured by FACS (N = 6). Two-way ANOVA followed by Tukey’s multiple-comparisons test (*p<0.05; **p<0.01; ***p<0.001), as depicted by lines. The data are represented as scatter plots, with each circle representing a single individual, means ± SEM are shown.

    Journal: eLife

    Article Title: Elevated glycolytic metabolism of monocytes limits the generation of HIF1A-driven migratory dendritic cells in tuberculosis

    doi: 10.7554/eLife.89319

    Figure Lengend Snippet: ( A, B ) Monocyte-derived DCs (Mo-DCs) were treated or not with the glycolysis inhibitor GSK2837808A and stimulated with iMtb. ( A ) Lactate release (N = 5). ( B ) Chemotactic activity toward CCL21 (N = 5). ( C, D ) Murine bone marrow-derived DCs (BMDCs) were treated or not with PX-478 or oxamate and stimulated with iMtb for 24 hr. ( C ) Lactate release (N = 3). ( D ) Representative dot blots showing the percentages of migrating BMDCs (CD11c + , CFSE-labeled) determined from inguinal lymph nodes. ( E ) Mo-DCs were stimulated with iMtb in the presence of either PX-478 or oxamate and CCR7 expression was measured by FACS (N = 6). Two-way ANOVA followed by Tukey’s multiple-comparisons test (*p<0.05; **p<0.01; ***p<0.001), as depicted by lines. The data are represented as scatter plots, with each circle representing a single individual, means ± SEM are shown.

    Article Snippet: Peptide, recombinant protein , Recombinant Human Exodus-2 (CCL21) , Peprotech , Cat# 300-35A , .

    Techniques: Derivative Assay, Activity Assay, Labeling, Expressing

    Tolerogenic Mo-DCs were generated by dexamethasone (Dx) treatment and were stimulated (or not) with irradiated Mycobacterium tuberculosis (iMtb) in the presence or absence of HIF1A activator dimethyloxalylglycine (DMOG). ( A ) Lactate release and glucose uptake as measured in supernatant (N = 8). ( B ) Mean fluorescence intensity (MFI) of HIF1A. Representative histograms and quantification are shown (N = 6). ( C ) Three-dimensional amoeboid migration of DCs through a collagen matrix. After 24 hr of migration, images of stacks within the matrix were taken every 30 µm. Percentage of migrating cells was defined as cells in the stacks within the matrix relative to total number of cells (N = 6). ( D ) Chemotactic activity toward CCL21 in vitro (N = 6). ( E–H ) Mo-DCs were generated from healthy subjects (HS) or TB patients, and DCs were stimulated (or not) with iMtb. ( E ) Chemotaxis index toward CCL21 (relative to unstimulated DCs) (N = 6). ( F ) Lactate production ratio relative to unstimulated DCs (N = 6). ( G ) Glycolytic capacity assessed by SCENITH (N = 4). ( H ) Chemotactic activity toward CCL21 of Mo-DCs from TB patients stimulated with iMtb and treated or not with DMOG (N = 6). Statistical significance assessed by ( A–D ) two-way ANOVA followed by Tukey’s multiple-comparisons test (*p<0.05; **p<0.01); ( E–G ) unpaired t -test (*p<0.05); ( H ) paired t -test (*p<0.05). The data are represented as scatter plots, with each circle representing a single individual, means ± SEM are shown.

    Journal: eLife

    Article Title: Elevated glycolytic metabolism of monocytes limits the generation of HIF1A-driven migratory dendritic cells in tuberculosis

    doi: 10.7554/eLife.89319

    Figure Lengend Snippet: Tolerogenic Mo-DCs were generated by dexamethasone (Dx) treatment and were stimulated (or not) with irradiated Mycobacterium tuberculosis (iMtb) in the presence or absence of HIF1A activator dimethyloxalylglycine (DMOG). ( A ) Lactate release and glucose uptake as measured in supernatant (N = 8). ( B ) Mean fluorescence intensity (MFI) of HIF1A. Representative histograms and quantification are shown (N = 6). ( C ) Three-dimensional amoeboid migration of DCs through a collagen matrix. After 24 hr of migration, images of stacks within the matrix were taken every 30 µm. Percentage of migrating cells was defined as cells in the stacks within the matrix relative to total number of cells (N = 6). ( D ) Chemotactic activity toward CCL21 in vitro (N = 6). ( E–H ) Mo-DCs were generated from healthy subjects (HS) or TB patients, and DCs were stimulated (or not) with iMtb. ( E ) Chemotaxis index toward CCL21 (relative to unstimulated DCs) (N = 6). ( F ) Lactate production ratio relative to unstimulated DCs (N = 6). ( G ) Glycolytic capacity assessed by SCENITH (N = 4). ( H ) Chemotactic activity toward CCL21 of Mo-DCs from TB patients stimulated with iMtb and treated or not with DMOG (N = 6). Statistical significance assessed by ( A–D ) two-way ANOVA followed by Tukey’s multiple-comparisons test (*p<0.05; **p<0.01); ( E–G ) unpaired t -test (*p<0.05); ( H ) paired t -test (*p<0.05). The data are represented as scatter plots, with each circle representing a single individual, means ± SEM are shown.

    Article Snippet: Peptide, recombinant protein , Recombinant Human Exodus-2 (CCL21) , Peprotech , Cat# 300-35A , .

    Techniques: Generated, Irradiation, Fluorescence, Migration, Activity Assay, In Vitro, Chemotaxis Assay

    ( A ) Ex vivo determination of HIF1A expression by monocytes from healthy subjects (HS) or TB patients (TB) for each monocyte subset (CD14 + CD16 - , CD14 + CD16 + , and CD14 dim CD16 + ) (N = 6). ( B, C ) Monocytes from HS were treated with dimethyloxalylglycine (DMOG) during the first 24 hr of differentiation with IL-4/GM-CSF (earlyDMOG) and removed afterward. On day 6 of differentiation, cells were stimulated (or not) with irradiated Mycobacterium tuberculosis (iMtb). ( B ) Monocyte lactate release after 24 hr of DMOG addition (N = 4). ( C ) Chemotactic activity toward CCL21 of DCs (N = 5). Statistical significance was assessed by ( B ) paired t -test (p<0.01); ( C ) two-way ANOVA followed by Tukey’s multiple-comparisons test (*p<0.05). The data are represented as scatter plots, with each circle representing a single individual, means ± SEM are shown.

    Journal: eLife

    Article Title: Elevated glycolytic metabolism of monocytes limits the generation of HIF1A-driven migratory dendritic cells in tuberculosis

    doi: 10.7554/eLife.89319

    Figure Lengend Snippet: ( A ) Ex vivo determination of HIF1A expression by monocytes from healthy subjects (HS) or TB patients (TB) for each monocyte subset (CD14 + CD16 - , CD14 + CD16 + , and CD14 dim CD16 + ) (N = 6). ( B, C ) Monocytes from HS were treated with dimethyloxalylglycine (DMOG) during the first 24 hr of differentiation with IL-4/GM-CSF (earlyDMOG) and removed afterward. On day 6 of differentiation, cells were stimulated (or not) with irradiated Mycobacterium tuberculosis (iMtb). ( B ) Monocyte lactate release after 24 hr of DMOG addition (N = 4). ( C ) Chemotactic activity toward CCL21 of DCs (N = 5). Statistical significance was assessed by ( B ) paired t -test (p<0.01); ( C ) two-way ANOVA followed by Tukey’s multiple-comparisons test (*p<0.05). The data are represented as scatter plots, with each circle representing a single individual, means ± SEM are shown.

    Article Snippet: Peptide, recombinant protein , Recombinant Human Exodus-2 (CCL21) , Peprotech , Cat# 300-35A , .

    Techniques: Ex Vivo, Expressing, Irradiation, Activity Assay

    Journal: eLife

    Article Title: Elevated glycolytic metabolism of monocytes limits the generation of HIF1A-driven migratory dendritic cells in tuberculosis

    doi: 10.7554/eLife.89319

    Figure Lengend Snippet:

    Article Snippet: Peptide, recombinant protein , Recombinant Human Exodus-2 (CCL21) , Peprotech , Cat# 300-35A , .

    Techniques: Recombinant, Enzyme-linked Immunosorbent Assay, Sequencing, Software

    Association between CCL21 levels and immunotherapy response in HCC. A Transcriptome analysis showed that CCL21 was upregulated in responders. B Serum CCL21 levels of responders and non-responders in the training cohort. C Using the median serum CCL21 concentration (1736 pg/ml) as the cutoff value, the proportion of responders and non-responders in different serum CCL21 levels. D Serum CCL21 levels of responders and non-responders in the validation cohort. E Using the median serum CCL21 concentration of training cohort as the cutoff value, the proportion of responders and non-responders in different serum CCL21 levels. F ROC curve analysis of predictive performance of high serum CCL21 level for predicting immunotherapy response in training and validation cohorts. One-way ANOVA with a post hoc LSD test. Categorical variables were presented as n (%) and constituent ratio between groups was compared using Pearson χ 2 and Fisher’s exact test. HCC, hepatocellular carcinoma; CCL21, Chemokine C–C motif ligand 21; ROC curve analysis, receiver operating characteristic curve analysis

    Journal: Cancer Immunology, Immunotherapy

    Article Title: Chemokine CCL21 determines immunotherapy response in hepatocellular carcinoma by affecting neutrophil polarization

    doi: 10.1007/s00262-024-03650-4

    Figure Lengend Snippet: Association between CCL21 levels and immunotherapy response in HCC. A Transcriptome analysis showed that CCL21 was upregulated in responders. B Serum CCL21 levels of responders and non-responders in the training cohort. C Using the median serum CCL21 concentration (1736 pg/ml) as the cutoff value, the proportion of responders and non-responders in different serum CCL21 levels. D Serum CCL21 levels of responders and non-responders in the validation cohort. E Using the median serum CCL21 concentration of training cohort as the cutoff value, the proportion of responders and non-responders in different serum CCL21 levels. F ROC curve analysis of predictive performance of high serum CCL21 level for predicting immunotherapy response in training and validation cohorts. One-way ANOVA with a post hoc LSD test. Categorical variables were presented as n (%) and constituent ratio between groups was compared using Pearson χ 2 and Fisher’s exact test. HCC, hepatocellular carcinoma; CCL21, Chemokine C–C motif ligand 21; ROC curve analysis, receiver operating characteristic curve analysis

    Article Snippet: Subsequently, to investigate the influence of CCL21 on neutrophil functional polarization, we stimulated neutrophils with 100 ng/ml recombinant human CCL21 (Cat. 300-35A, PeproTech) for 3 h and then used for subsequent experiments.

    Techniques: Concentration Assay, Biomarker Discovery

    CCL21 inhibits neutrophil N2 polarization through regulating NF-κB signaling pathway. A Schematic diagram of neutrophil isolation and culture in vitro. B qPCR analysis of the transcription of N1 and N2 markers in neutrophils treated with or without recombinant human CCL21. C Flow cytometry analysis of CD206 expression of neutrophils in indicated groups. D Heatmap of the differential genes in negative control and CCL21 treatment groups. E Differentially enriched pathways in negative control and CCL21 treatment groups identified by GSEA. F Western blot of NF-κB pathway in neutrophils treated with or without recombinant human CCL21. G qPCR analysis of the transcription of N1 and N2 markers in neutrophils treated with or without recombinant human CCL21 and/or NF-κB activator 1. H Flow cytometry analysis of CD206 expression of neutrophils in indicated groups. One-way ANOVA with a post hoc LSD test. CCL21, Chemokine C–C motif ligand 21; qPCR, quantitative real- time PCR; GSEA, gene set enrichment analysis; NF-κB, nuclear factor kappa B

    Journal: Cancer Immunology, Immunotherapy

    Article Title: Chemokine CCL21 determines immunotherapy response in hepatocellular carcinoma by affecting neutrophil polarization

    doi: 10.1007/s00262-024-03650-4

    Figure Lengend Snippet: CCL21 inhibits neutrophil N2 polarization through regulating NF-κB signaling pathway. A Schematic diagram of neutrophil isolation and culture in vitro. B qPCR analysis of the transcription of N1 and N2 markers in neutrophils treated with or without recombinant human CCL21. C Flow cytometry analysis of CD206 expression of neutrophils in indicated groups. D Heatmap of the differential genes in negative control and CCL21 treatment groups. E Differentially enriched pathways in negative control and CCL21 treatment groups identified by GSEA. F Western blot of NF-κB pathway in neutrophils treated with or without recombinant human CCL21. G qPCR analysis of the transcription of N1 and N2 markers in neutrophils treated with or without recombinant human CCL21 and/or NF-κB activator 1. H Flow cytometry analysis of CD206 expression of neutrophils in indicated groups. One-way ANOVA with a post hoc LSD test. CCL21, Chemokine C–C motif ligand 21; qPCR, quantitative real- time PCR; GSEA, gene set enrichment analysis; NF-κB, nuclear factor kappa B

    Article Snippet: Subsequently, to investigate the influence of CCL21 on neutrophil functional polarization, we stimulated neutrophils with 100 ng/ml recombinant human CCL21 (Cat. 300-35A, PeproTech) for 3 h and then used for subsequent experiments.

    Techniques: Isolation, In Vitro, Recombinant, Flow Cytometry, Expressing, Negative Control, Western Blot, Real-time Polymerase Chain Reaction

    CCL21 enhances the efficacy of anti-PD-1 antibody in HCC in vivo. A Schematic diagram of anti-PD-1 antibody and recombinant murine CCL21 treatment in the mice model of HCC subcutaneous tumors. B The volume of subcutaneous tumors in each group during treatment. C Gross appearance of the subcutaneous HCC tumors from the indicated treatment groups. D The weight of subcutaneous tumors in each group at the endpoint. E – G Flow cytometry analyses of CD206 expression of neutrophils and the tumor infiltration percentage of CD3 + CD8 + T cells in each group. H Schematic diagram depicting that CCL21 determines immunotherapy response in HCC by affecting neutrophil polarization. One-way ANOVA with a post hoc LSD test. CCL21, Chemokine C–C motif ligand 21; PD-1, programmed death receptor 1; HCC, hepatocellular carcinoma

    Journal: Cancer Immunology, Immunotherapy

    Article Title: Chemokine CCL21 determines immunotherapy response in hepatocellular carcinoma by affecting neutrophil polarization

    doi: 10.1007/s00262-024-03650-4

    Figure Lengend Snippet: CCL21 enhances the efficacy of anti-PD-1 antibody in HCC in vivo. A Schematic diagram of anti-PD-1 antibody and recombinant murine CCL21 treatment in the mice model of HCC subcutaneous tumors. B The volume of subcutaneous tumors in each group during treatment. C Gross appearance of the subcutaneous HCC tumors from the indicated treatment groups. D The weight of subcutaneous tumors in each group at the endpoint. E – G Flow cytometry analyses of CD206 expression of neutrophils and the tumor infiltration percentage of CD3 + CD8 + T cells in each group. H Schematic diagram depicting that CCL21 determines immunotherapy response in HCC by affecting neutrophil polarization. One-way ANOVA with a post hoc LSD test. CCL21, Chemokine C–C motif ligand 21; PD-1, programmed death receptor 1; HCC, hepatocellular carcinoma

    Article Snippet: Subsequently, to investigate the influence of CCL21 on neutrophil functional polarization, we stimulated neutrophils with 100 ng/ml recombinant human CCL21 (Cat. 300-35A, PeproTech) for 3 h and then used for subsequent experiments.

    Techniques: In Vivo, Recombinant, Flow Cytometry, Expressing